Study of Patients With Drug-induced Non-variceal Upper Gastrointestinal Bleeding
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
* To study the association between non-variceal UGIB and the use of NSAIDs, VKAs, DOACs and antiplatelet therapy. * To compare the severity of bleeding related to specified drugs. * To determine risk factors associated with non-variceal UGIB.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adult patients (aged 18 years and above) presented with signs and symptoms of UGIB (hematemesis and/or melena)
Disqualifiers
Variceal bleeding
Age below 18 years
Pregnant women
Consent refusal
Trial population
Adult patients (aged 18 years and above) presented either to the emergency or the outpatient department with signs and symptoms of UGIB (hematemesis and/or melena) who are on the specified medications (NSAIDs, VKAs, DOACs and antiplatelet therapy).
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Upper endoscopy
Procedure/SurgeryAll patients will do gastroscopy (upper endoscopy) within the first 24 hour of admission and specific elements of bleeding
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Association between non-variceal UGIB and the use of different drugs
observation the association between the incedience of Non-variceal upper Gastrointestinal Bleeding and the use of NSAIDs, VKAs, DOACs and antiplatelet therapy
Time frame
through study completion, an average of 1 yearSecondary outcomes
1
The severity of Non-variceal bleeding related to specified drugs.
To compare the severity of Non-variceal bleeding related to specified drugs, according to Rockall Score
Time frame
through study completion, an average of 1 year2
Risk factors associated with non-variceal upper gastrointestinal bleeding
We will determine risk factors associated with With non-varicreal gastrointestinal bleeding, such as demographic data, smoking , co-morbidities ، dose and duration of specified drugs, and presence of h pylori infection.
Time frame
through study completion, an average of 1 yearLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: